aTyr Pharma Inc. (ATYR) is approaching a key clinical trial catalyst this quarter, as it prepares to report data for its lead asset, Efzofitimod.
Efzofitimod works by selectively modulating the neuropilin-2 receptor protein, which downregulates both innate and adaptive immune responses in inflammatory disease states. Both innate and adaptive immune responses offer defense against various kinds of pathogens. While adaptive immunity develops over time and is more specific to pathogens, innate immunity is the body's first line of defense and is present from birth.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.